Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital downgrades CVS Group on CMA review

(Sharecast News) - RBC Capital Markets downgraded CVS Group on Friday to 'sector perform' from 'outperform' and slashed the price target to 1,200p from 2,100p after the UK Competition and Markets Authority said it had provisionally decided to launch a formal investigation into the vet market. RBC said the decision "casts a pall over the industry that is unlikely to be resolved for 18-21 months".

"Based on our new scenario analysis, published today in our industry report, CVS' shares are significantly over-discounting the risk, based on our scenario analysis, but we doubt this valuation discrepancy will attract new investors until closer to a more final CMA outcome," the bank said.

RBC said the price target was cut only on the basis of lack of news flow. It said investors may struggle to get excited about the stock until closer to the end of the investigation or, indeed, after full resolution.

"We think investors with an 18-24 month investment horizon should see the current price as a great opportunity to buy shares with almost 3x upside potential which on a worst-case basis is the upside when applying 13x to Jun-26 EBITDA," it said.

"Investors focused on nearer-term performance are likely to take a view that shares will go sideways for now.

"Our new £12/share price target is based on a rather arbitrary 50% discount to current 'fair value' to account for the perception around CMA risk."

Share this article

Related Sharecast Articles

Goldman Sachs downgrades SSP to 'sell', prefers WH Smith
(Sharecast News) - Goldman Sachs downgraded SSP on Monday to 'sell' from 'neutral' "on a relative basis" as it took a look at European travel concessions.
UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.